Literature DB >> 11840146

Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

K Matsue1, T Tabayashi, K Yamada, M Takeuchi.   

Abstract

Persistence of bcr-abl transcripts after marrow grafting is thought to convey a high risk for relapse in patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). Donor leukocyte infusion (DLI) is closely associated with development of graft-versus-host disease (GVHD) and has well-defined activity against relapsed chronic myelogenous leukemia (CML) but not ALL. We report two patients with Ph-positive ALL who remained bcr-abl positive by reverse transcriptase polymerase chain reaction (RT-PCR) after marrow grafting. Residual bcr-abl transcripts in both patients were eliminated following acute GVHD, which was induced by either DLI or rapid reduction of immunosuppression. Both patients have continued in complete molecular remission for 18 months and 8 months following transplantation, respectively. Our observation suggests that induction of GVHD may eliminate minimal residual disease, thereby preventing leukemia relapse in patients transplanted for Ph-positive ALL.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11840146     DOI: 10.1038/sj.bmt.1703318

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  5 in total

Review 1.  Clinical applications of BCR-ABL molecular testing in acute leukemia.

Authors:  Amgad L Nashed; Kathleen W Rao; Margaret L Gulley
Journal:  J Mol Diagn       Date:  2003-05       Impact factor: 5.568

2.  Successful treatment of minimal residual disease-positive Philadelphia chromosome-positive acute lymphoblastic leukemia with imatinib followed by reduced-intensity unrelated cord blood transplantation after allogeneic peripheral blood stem cell transplantation.

Authors:  Akiyoshi Takami; Shigeru Shimadoi; Chiharu Sugimori; Kenichi Takemoto; Masami Shibayama; Tomotaka Yoshida; Tohru Murayama; Kenichi Nagai; Koichi Miyamura; Hidesaku Asakura; Shinji Nakao
Journal:  Int J Hematol       Date:  2006-08       Impact factor: 2.490

Review 3.  Twenty years' experience in allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in the Nagoya Blood and Marrow Transplantation Group.

Authors:  Hiroatsu Iida; Hiroshi Sao; Kenjiro Kitaori; Seiichi Gotoh; Makoto Yazaki; Seiji Kojima; Atsushi Wakita; Yasuo Morishima; Yoshihisa Kodera; Yoshihisa Morishita
Journal:  Int J Hematol       Date:  2004-01       Impact factor: 2.490

Review 4.  Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  A K Fielding; G A Zakout
Journal:  Curr Hematol Malig Rep       Date:  2013-06       Impact factor: 3.952

5.  Rapid improvement of disseminated intravascular coagulation by donor leukocyte infusions in a patient with promyelocytic crisis of chronic myelogenous leukemia after reduced-intensity stem cell transplantation from an HLA 2-antigen-mismatched mother.

Authors:  Kosei Matsue; Konagi Yamada; Masami Takeuchi; Takayuki Tabayashi
Journal:  Int J Hematol       Date:  2003-05       Impact factor: 2.490

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.